XORTX Therapeutics Inc.

XORTX Therapeutics is a late clinical-stage biotechnology company focused on identifying, developing and potentially commercializing therapies to treat diseases modulated by aberrant purine and uric acid metabolism in indications such as gout, autosomal dominant polycystic kidney disease (“ADPKD”) an orphan (rare) disease and larger, more prevalent type 2 diabetic nephropathy (“T2DN”) as well as acute kidney injury (“AKI”) associated with respiratory virus infection. In addition, XORTX has expanded interest to include anti-fibrotic medicine in kidney disease.

Current securities

1. 6-K filingSep 18, 2026
2. 6-K filingSep 10, 2026
3. 6-K filingSep 9, 2026
4. 6-K filingAug 28, 2026
5. 6-K filingAug 17, 2026